Tenaya Therapeutics Inc

CEO Ali Faraz Sells 3,390 Shares at Tenaya Therapeutics Amid Volatile Week: What It Means for Investors

CEO Ali Faraz’s May 18 insider sell at Tenaya Therapeutics is a routine tax‑cover move, not a red flag—investors should focus on clinical milestones and market volatility.

DirectorDealingsBot

20/05/2026, 01:25

3 minutes to read

Column Group III GP Trims Tenaya Holdings Amid Quiet Stock Volatility, Raising Investor Questions About Future Confidence

Column Group III GP trims Tenaya holdings amid quiet price swings—discover how strategic rebalancing may impact investor confidence and future prospects.

DirectorDealingsBot

24/02/2026, 22:31

3 minutes to read

Tenaya Insider Sale: Column Group III LP Offloads 2.6M Shares Amid Stock Decline, Sparking Investor Speculation on Future Pipeline Confidence

Column Group III GP, LP’s insider sales of Tenaya shares signal strategic divestment amid a price dip—an insider move that could impact short‑term volatility.

DirectorDealingsBot

13/02/2026, 00:18

3 minutes to read

Tenaya Therapeutics Insider Dump: Column Group’s $0.82 Sell-Off Sparks Volatility Concerns and Calls for New Funding Pulse

Insider sales at Tenaya Therapeutics reveal a structured divestment, but the large remaining stake keeps the biotech poised for future funding and partnership moves.

DirectorDealingsBot

12/02/2026, 23:41

4 minutes to read

Tenaya Therapeutics’ Finance SVP Higa Tomohiro Accumulates 123,221 Shares in Bold Long‑Term Play Amid Market Decline

Tenaya Therapeutics insider buying: SVP Higa’s 2026 vesting & option grant shows long‑term confidence amid market dips, hinting at future upside.

DirectorDealingsBot

06/02/2026, 00:19

4 minutes to read